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ABBREVIATIONS AND ACRONYMS
AIDS acquired immunodeficiency syndrome
ART antiretroviral therapy
ATS amphetamine-type stimulants
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CBT  cognitive–behavioural therapy
EC European Commission
EMCDDA European Monitoring Centre for Drugs and Drug Addiction
FHI Family Health International
GFATM Global Fund to fight AIDS, Tuberculosis and Malaria
HAV hepatitis A virus
HBV hepatitis B virus
HCV hepatitis C virus
HIV human immunodeficiency virus
IDU injecting drug user
IEC information, education and communication
MERG monitoring and evaluation reference group 
NCPI National Composite Policy Index
NSP needle and syringe programme
OST opioid substitution therapy
PITC provider-initiated testing and counselling
PMTCT prevention of mother-to-child transmission (of HIV)
SEARO Regional Office for South-East Asia (of WHO) 
STI sexually transmitted infection
T&C testing and counselling
TB tuberculosis
UIC unique identifier code
UN United Nations
UNAIDS Joint United Nations Programme on HIV/AIDS
UNFPA United Nations Population Fund
UNGASS United Nations General Assembly Special Session 
UNODC United Nations Office on Drugs and Crime
WHO World Health Organization
WPRO Regional Office for the Western Pacific (of WHO)
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1. INTRODUCTION
This document provides technical guidance to coun-
tries on setting ambitious, but achievable national 
targets for scaling up towards universal access to 
HIV/AIDS prevention, treatment and care for inject-
ing drug users (IDUs). 
This document has been developed collaboratively 
by three United Nations (UN) agencies (the World 
Health Organization [WHO], United Nations Office 
on Drugs and Crime [UNODC] and Joint United 
Nations Programme on HIV/AIDS [UNAIDS]) and 
international experts in the field. It builds on previ-
ous UNODC1 and UNAIDS2 guidelines and adheres 
to the principles therein. It serves to provide more 
consistent methods of measuring and compar-
ing countries’ progress towards national targets to 
scale up comprehensive programmes for universal 
access to prevention, treatment, care and support 
for HIV/AIDS by 2010.3,4 These aims are based upon 
the 2006 Political Declaration on HIV/AIDS at which 
countries committed to scale up towards universal 
access, and the earlier Declaration of Commitment 
on HIV/AIDS.5 The UNAIDS Secretariat and its 
cosponsors supported the launch of this broader 
effort with more specific operational guidance to 
countries.3,4,6,7,76
This Technical guide provides countries with:
◗ A framework and process to set national targets
◗ A comprehensive package of core interventions 
for IDUs
◗ A set of indicators and indicative targets (or 
“benchmarks”) to be used to set programmatic 
objectives, and monitor and evaluate HIV inter-
ventions for IDUs
◗ Examples of data sources.
This framework could be applied by countries that 
wish to follow a systematic review process when 
setting, reviewing or adjusting targets for HIV pre-
vention among IDUs. This Technical guide and the 
process outlined above are intended to assist agen-
cies and individuals involved in planning programmes 
for universal access. They can also be used for other 
purposes such as preparing proposals for or report-
ing on programmes to various donor organizations 
including the Global Fund to fight AIDS, Tuberculosis 
and Malaria (GFATM), the European Commission 
(EC) or other multilateral and bilateral funding 
sources. 
Although primarily intended for national target-set-
ting, this Guide will also be useful in setting targets 
for regions in large countries (for example, states/
provinces in China, provinces in Viet Nam, or oblasts 
in the Russian Federation), for smaller geographical 
areas such as cities and for specific settings such 
as prisons. It is important to define the scope of the 
areas or settings under consideration. While this 
Technical guide focuses primarily on IDUs, it may 
also be useful for setting targets for HIV interven-
tions targeting problematic drug users who do not 
inject but who are at risk of starting to do so.
This version of the Guide represents an initial attempt 
to develop a framework for assessing countries’ 
progress in delivering a comprehensive package of 
core interventions. This framework and the recom-
mended target levels are based on the limited body 
of evidence currently available in this area. Over 
time, as more evidence becomes available and as 
experience is gained in the field from applying this 
framework, this Guide will be revised accordingly. A 
monitoring and evaluation reference group (MERG) 
convened by UNAIDS is in the process of further 
developing methods and guidelines for measuring 
the coverage and quality of HIV prevention and care 
services for at-risk populations, including IDUs. It is 
anticipated that these efforts will complement and 
enhance this Technical guide.
This Technical guide is scheduled to be reviewed 
and revised in 2010. 
6 WHO, UNODC, UNAIDS TECHNICAL GUIDE  WHO DEPARTMENT OF HIV/AIDS  7
Further information on the evidence in support of these interventions is available:
◗ The WHO/UNODC Evidence for Action series and policy briefs:9
http://www.who.int/hiv/pub/idu/idupolicybriefs/en/index.html
◗ Committee on the Prevention of HIV Infection among Injecting Drug Users in High-Risk Countries, 
Institute of Medicine. Preventing HIV infection among injecting drug users in high-risk countries an 
assessment of the evidence. Washington, DC, USA, The National Academies Press, 2006.77
Guidance on counselling and testing is available:
◗ WHO & UNAIDS. Guidance on provider-initiated HIV testing and counselling in health facilities. Geneva, 
WHO, 2007.17
◗ WHO Regional Office for South-East Asia (SEARO), WHO Regional Office for the Western Pacific 
(WPRO) & UNODC. Guidance on testing and counselling for HIV in settings attended by people who 
inject drugs: improving access to treatment, care and prevention. Manila, WHO WPRO, 2009 (in press)18
2.1 The comprehensive 
package
Preventing HIV transmission through injecting drug 
use is one of the key challenges to universal access 
in the health sector. A comprehensive package for 
the prevention, treatment and care of HIV among 
IDUs includes the following nine interventions:
1. Needle and syringe programmes (NSPs)
2. Opioid substitution therapy (OST) and other 
drug dependence treatment
3. HIV testing and counselling (T&C)
4. Antiretroviral therapy (ART)
5. Prevention and treatment of sexually transmitted 
infections (STIs) 
6. Condom programmes for IDUs and their sexual 
partners
7. Targeted information, education and communi-
cation (IEC) for IDUs and their sexual partners 
8. Vaccination, diagnosis and treatment of viral 
hepatitis 
9. Prevention, diagnosis and treatment of 
tuberculosis (TB). 
These nine interventions are included in the com-
prehensive package because they have the greatest 
impact on HIV prevention and treatment. There is a 
wealth of scientific evidence supporting the efficacy of 
these interventions in preventing the spread of HIV.8,77 
With rare exceptions, studies consistently show that 
needle and syringe programmes (NSPs) result in 
marked decreases in HIV transmission, by as much 
as 33–42% in some settings.10–12
Opioid substitution therapy (OST), with metha-
done or buprenorphine, is highly effective in reduc-
ing injecting behaviours that put injectors at risk for 
HIV.13 In addition, OST has been demonstrated to 
improve both access and adherence to ART, and 
reduce mortality.14–16 
HIV testing and counselling (T&C) is an important gate-
way to HIV treatment and care including ART. In some 
circumstances, provider-initiated HIV testing and counsel-
ling (PITC) for IDUs is recommended. WHO and UNODC 
are in the process of developing guidance on HIV T&C for 
most-at-risk populations, including prisoners and IDUs.
In general, IDUs have poorer levels of access to ART 
compared with non-IDUs, despite the fact that provi-
sion of ART to IDUs has population-wide health ben-
efits and despite evidence that IDUs can success-
fully undergo treatment and benefit from ART.19–21
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The currently available evidence for the impact of 
other forms of drug dependence treatment on HIV 
risk behaviour is less compelling22 but remains 
strongly recommended for countries where non-
opioid drugs such as amphetamine-type stimulants 
(ATS), cocaine and benzodiazepines are widely 
used. Such treatment should be evidence-based 
and might include cognitive–behavioural therapy 
(CBT)23 and contingency management for amphet-
amine dependence.24 
Interventions to reduce the sexual risk behaviours of 
IDUs, including condom provision and improved access 
to sexual health services, generally have a more mod-
est impact on HIV transmission than those that reduce 
injecting risk behaviours.26, 27 However, the importance 
of such interventions is generally accepted; in particu-
lar with regard to condom provision, and prevention 
and treatment of STIs among female injectors, esp-
ecially those who engage in sex work.78 
Although the evidence base for targeted informa-
tion, education and communication (IEC) for IDUs 
and their sexual partners is relatively weak com-
pared with that for NSPs and OST, it is included in 
the comprehensive package because, when com-
bined with other measures, a more positive and 
sustained impact upon HIV risk behaviours can be 
achieved with these interventions.8,28
IDUs may have increased risk of acquiring TB and in 
particular as a coinfection with HIV. In response, the 
comprehensive package also includes the preven-
tion, diagnosis and treatment of TB. 
While each of these separate interventions is useful 
in addressing HIV prevention and care among IDUs, 
it is important to recognize that they form part of 
a package and have the greatest beneficial impact 
when delivered together. 
A number of interventions have not been included in 
the comprehensive package because of the relative 
lack of evidence of their effectiveness or other con-
siderations. These include supervised injection sites, 
which remain controversial, but are demonstrating 
effectiveness in a small number of countries where 
they have been implemented and evaluated.30,31
In addition, there are other interventions that are not 
included in the comprehensive package but are also 
important and should not be overlooked. For exam-
ple, as is the case for non-injectors, it is critical to 
consider the prevention of mother-to-child transmis-
sion (PMTCT) in the case of HIV-positive pregnant 
women who may inject drugs. 
Although this Guide focuses primarily on HIV preven-
tion, these interventions also have utility with regard 
to the prevention of other bloodborne viruses; in 
particular hepatitis C virus (HCV), which IDUs are at 
particular risk for acquiring.33 
Treatnet (www.unodc.org/treatment/index.html),25 the UNODC-supported international network of 
drug dependence treatment and rehabilitation resource centres, aims at improving the quality of drug 
dependence treatment through information exchange, cooperation among, and empowerment of, twenty 
selected resource centres representing all regions. The twenty centres and all the rest of the network’s 
members are committed to the synthesis, demonstration and dissemination of good practices, and appli-
cation of state-of-the-art approaches to effective treatment and rehabilitation of drug dependence.
Guidance is available on providing TB services for IDUs: 
◗ WHO, UNODC, UNAIDS. Evidence for Action Technical Papers. Policy guidelines for collaborative TB 
and HIV services for injecting and other drug users – an integrated approach. Geneva, WHO, 2008.29
Guidance is available on the prevention of mother-to-child transmission: 
◗ WHO and partners. Guidance on global scale-up of the prevention of mother-to-child transmission of 
HIV: towards universal access for women, infants and young children and eliminating HIV and AIDS 
among children. Geneva, WHO, 2007.32 Available at: 
 http://whqlibdoc.who.int/publications/2007/9789241596015_eng.pdf 
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Community-based outreach is not included as a sep-
arate intervention in the comprehensive package. 
However, it is recommended as an extraordinarily 
effective method of accessing IDUs, an often diffi-
cult group to access.36 Outreach is a highly effective 
means of delivering HIV/AIDS prevention interven-
tions such as NSPs, condom programmes and tar-
geted IEC to IDUs, as well as a useful access point 
for the referral of IDUs to interventions such as OST 
and ART. Outreach is very strongly recommended as 
a method of service delivery and as an essential com-
ponent of all HIV prevention and care programmes. 
These interventions are also appropriate for prisons 
and other closed settings (for example, compulsory 
treatment and rehabilitation centres). The principle 
of equivalency of care37 demands that prisoners are 
entitled, without discrimination, to the same stan-
dard of health care that is found in the outside com-
munity, including preventive measures and ART. The 
framework presented here can also be applied to 
evaluate and set targets for HIV prevention and care 
programmes in prisons. 
For a discussion on access to HCV treatment in the United States and the European Union:
◗ Wiessing L. The access of injecting drug users to hepatitis C treatment is low and should be improved. 
Eurosurveillance, 2001, 5 (31):pii=1709.34
For an inventory of HCV treatment guidelines in Western Europe:
◗ Reimer J et al. Guidelines for the treatment of hepatitis C virus infection in injection drug users: status 
quo in the European Union countries. Clinical Infectious Diseases, 2005, 40 (Suppl. 5):S373–S378.35
Further information on outreach is available: 
◗ WHO. Evidence for Action: effectiveness of community-based outreach in preventing HIV/AIDS among 
injecting drug users. Geneva, World Health Organization, 2004.36
◗ UNAIDS. Practical guidelines for intensifying HIV prevention. Geneva, Switzerland, Joint United Nations 
Programme on HIV/AIDS, 2007.79
Guidance and further information on HIV prevention and treatment in prisons and other closed 
settings is available:
◗ WHO. Status paper on prisons, drugs and harm reduction. Copenhagen, World Health Organization 
Regional Office for Europe, 2005.38
◗ WHO, UNODC, UNAIDS. Evidence for action on HIV/AIDS and injecting drug use. Policy Brief: reduc-
tion of HIV transmission in prisons. Geneva, WHO, 2004.12
◗ WHO, UNODC, UNAIDS. Evidence for action technical papers. Effectiveness of interventions to 
address HIV in prisons. Geneva, WHO, 2007.39 Available at: http://www.who.int/hiv/idu/OMS_
E4Acomprehensive_WEB.pdf
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2.2 Universal access
Universal acccess was adopted at the High-Level 
Meeting on HIV/AIDS in 2006 as a commitment to 
scale up national programmes for HIV treatment, 
prevention, care and support for all those who need 
it. While clearly an ambitious and desirable goal, 
universal access is also a concrete process driven 
by countries who have organized national consulta-
tions to identify critical obstacles to scaling up, and 
planned measures to address these. 
Universal access encompasses the principles of 
equality, sustainability, comprehensiveness, acces-
sibility and sustainability, which guide the develop-
ment of interventions in the comprehensive pack-
age. These must:
◗ Be physically accessible (geographically distributed, 
e.g. available not only in major cities or unavailable 
in hard-to-reach locations such as prisons);
◗ Be affordable (cost at the point of service should 
not be a barrier, e.g. patients should not have to 
pay for their treatment);
◗ Be equitable and non-discriminatory (there 
should be no exclusion criteria except medi-
cal ones, e.g. OST should not be limited to only 
those IDUs who are HIV-infected or who have 
failed on other drug dependence treatment);
◗ Be non-rationed (supply should be determined 
by need and not limited by cost or other consid-
erations, e.g. NSPs with strict limits on the num-
ber of syringes provided to each client are less 
successful than those that do not impose such 
restrictions).40
Access should not be restricted by sociodemo-
graphic or other criteria such as the following:
◗ Age: programmes should not have age restric-
tions, i.e. there should be no minimum age 
requirement for accessing services
◗ Sex/gender, sexual orientation and sexual 
behaviour
◗ Citizenship, nationality, country of origin, race/
ethnicity, asylum-seeking status, or religion/reli-
gious convictions
◗ Employment status and profession, including sex 
work, illegal employment, etc.
◗ Confinement to a facility/setting, imprisonment, 
military service, health institution, orphanage, etc.
◗ Health insurance status
◗ Substance use status – for example, current 
injecting should not be a barrier to access.
In addition, all interventions should be offered volun-
tarily in an enabling environment created by support-
ive legislation, policies and strategies.
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The following framework builds on the target-setting 
process for a comprehensive package of interven-
tions for universal access, as laid out in earlier opera-
tional guidelines. It provides more programmatic guid-
ance on the process of measuring and setting targets 
for the interventions of a comprehensive package.
For each of the nine interventions a series of indica-
tors are described. These indicators are intended to 
assess the following:
◗ Availability 
◗ Coverage 
◗ Quality 
◗ Potential impact 
Indicative target levels for key indicators are also 
described. 
As discussed above, maximum benefit is gained by 
implementing all nine parts of this comprehensive 
package together, and it is thus important to conduct 
ongoing monitoring and evaluation for each of these 
interventions. It is recognized, however, that coun-
tries are at different stages of establishing a compre-
hensive response, and that limitations may exist to 
how comprehensive the monitoring and evaluation 
process can be. It is advised that at least the first 
four of the nine interventions – NSP, OST, T&C and 
ART – be monitored as a minimum requirement. 
To be able to define indicators and set targets, it is 
necessary to understand the environment in which 
these interventions are being conducted and to 
define the populations that the interventions are 
intended to target.
Where possible, gender-disaggregated data should 
be collected and reported for these indicators. 
3.1 Environment
It is important to consider the context in which inject-
ing drug use occurs and services for IDUs are deliv-
ered. This involves identifying structural, societal 
and other factors that may impede the successful 
delivery of these interventions, and working towards 
creating a more supportive environment.
People who inject drugs are commonly marginalized 
and subject to stigma, discrimination and, due to the 
illegality of drug use, legal sanctions. Structural fac-
tors such as changes in drug supply or injection prac-
tices can impact upon HIV transmission. Legal and 
law enforcement conditions can act as barriers to the 
delivery and scaling up of HIV prevention services.
Means by which such barriers might be addressed 
include antidiscrimination legislation and ensuring 
that policing policy and practice does not impede the 
delivery of services. 
A number of items included in the National Composite 
Policy Index (NCPI) of the UNAIDS United Nations 
General Assembly Special Session (UNGASS) HIV 
monitoring and reporting process relate to IDUs. 
These can be used to help identify such barriers and 
assess progress.7 
3.2 Denominator populations
Many of the indicators described in this Guide 
comprise a numerator and denominator. Most of 
the denominators reflect defined populations that 
are the target of the intervention being assessed. 
Appropriate estimates should be used for the 
denominator for each of the interventions. These 
data, including national estimates of IDUs, need 
to be carefully reviewed and assessed in order to 
ensure that the denominators used in calculating the 
different target levels outlined in this Guide repre-
sent the population of interest in the numerator. 
◗ Estimating the size of IDU populations
Many different definitions of injecting drug use exist in 
the literature and are useful in different circumstances, 
depending upon the context and what is being inves-
tigated. For example, it is important to consider “cur-
rent” injecting drug use when planning NSPs. When 
trying to determine how many people in a population 
may have been exposed to HIV transmission via inject-
ing drug use, it is more appropriate to look at “lifetime 
injecting drug use”, or those who have ever injected 
since HIV was first present in that location. 
For the purpose of reporting on the indicators 
described in this Guide, it is recommended that 
IDUs be defined as those who have injected any 
time within the past 12 months. 
In some countries, people may self-inject medicines 
for medical purposes. This practice is commonly 
referred to as therapeutic injection and is distinct 
from injecting drug use, which is the focus of this 
Guide. Those who have self-injected medicines for 
medical purposes only are not included in the defini-
tion of injecting drug use given above. 
Determining the size of IDU populations can be chal-
lenging, particularly because they are a “hidden” 
3. THE TARGET-SETTING PROCESS
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population. Indirect estimation methods such as 
multiplier and benchmark calculations, which make 
use of existing data sources (police arrests, drug 
treatment, drug-related deaths) or capture–recap-
ture methods are extremely useful, and guidance on 
these methods is available.
Surveys of the general population such as household 
surveys generally underestimate the prevalence of 
injecting drug use because injectors are less likely to 
be included in the sample, and because drug inject-
ing is an illicit and stigmatized behaviour, so respon-
dents may be reluctant to disclose such use. 
If a range of estimates is available for a defined IDU 
population, possibly derived by different estimation 
processes, it is recommended that, every two years, 
a national expert group meeting be held of research-
ers and key informants from the government, non-
governmental organizations (NGOs) and the private 
sector to determine and update the consensus num-
bers or range of numbers for the denominator popu-
lation. These numbers or ranges can then be used by 
all researchers, government departments and others 
providing calculations related to those populations. 
◗ Estimating the size of the target population 
for different interventions
Determining the size of the populations that different 
interventions intend to target can be challenging. It 
is critical to clearly define the population in question.
 
While an NSP may target all drug users who inject, 
OST programmes will target dependent opioid users 
including both injectors and non-injectors, and it is 
necessary to estimate the size of these populations 
when measuring the coverage of these interventions. 
Separate estimates of subpopulations (e.g. problem 
drug users*, problematic non-injectors, injectors of 
non-opioid drugs as well as injectors of opioid drugs) 
are needed and, where relevant, used as denomi-
nator populations. The number of IDUs requiring 
access to ART and HCV, hepatitis B virus (HBV) and 
TB treatment and care must also be estimated. In 
many countries, IDUs have a disproportionately low 
* The European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) defines problem drug use as injecting drug use or long 
duration/regular use of opiates, cocaine and/or amphetamines. 
access to HIV/AIDS care and support. In most coun-
tries, current injectors are excluded from HIV inter-
ventions, in particular from ART.45 It is thus important 
to determine what proportion of current IDUs requir-
ing access to these interventions are in fact able to 
do so. “Current” drug injecting can be defined in 
many different ways but again, for the purpose of 
measuring these indicators, this can be defined as 
those who have injected any time within the 
past 12 months. 
◗ Gender disaggregation
Female IDUs often face additional barriers to access-
ing HIV prevention and care services. For this reason, 
it can be useful to collect gender-disaggregated data 
and use these along with gender-specific denomina-
tor estimates to assess and monitor this disparity. 
Further details on denominator populations are 
provided in the outline for each indicator.
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Guidance on estimation methods is available: 
◗ UNODC. Global Assessment Programme on dug abuse. Estimating prevalence: indirect methods for 
estimating the size of the drug problem. Vienna, UNODC, 2003.41
◗ Hickman M et al. Estimating the prevalence of problematic drug use: a review of methods and their 
application. UN Bulletin on Narcotics, 2002, 54:15–32.42
◗ U.S. Department of Health and Human Services, Centers for Disease Control, GAP Surveillance Team. 
Most at risk populations sampling strategies and design tool. HSS-CDC, 2009 (in press).43 Available at: 
http://www.igh.org/surveillance 
The Reference Group to the United Nations on HIV and injecting drug use undertakes reviews of 
the available literature to produce global and regional estimates of the number of people who inject drugs 
and the prevalence of HIV among this group. See www.idurefgroup.com for more details on the Reference 
Group and to access reported country-level and global-level estimates of injecting drug use and HIV among 
injectors. See also Mathers et al. 200844 for a recent review of available data on IDU prevalence.
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3.3  Availability of 
interventions
A comprehensive approach should include all 
the interventions in the comprehensive package. 
However, the mix of interventions and content of 
each intervention will be context-specific. This 
can be determined by a thorough assessment and 
understanding of the local situation including: 
◗ The types of services available
◗ Patterns of drug use and the types of drugs used 
(e.g. opioids, ATS, cocaine, benzodiazepines, 
etc.) 
◗ Rate and frequency of injecting.
Accordingly, the indicators used to assess these 
interventions need to appropriately match each 
intervention.
In some countries, NSPs will include access to 
clean equipment and its safe disposal through fixed 
or mobile exchange programmes and/or through 
pharmacies where equipment is available free of 
charge. In many countries, pharmacy sales of inject-
ing equipment are an important, and sometimes the 
most significant, source of clean injecting equip-
ment accessible to IDUs.46,47
It is advisable for countries to differentiate between 
modalities of delivery and have, for example, a sepa-
rate indicator for pharmacy sales. In countries where 
both modalities are available, it will be useful to have 
a measure of the proportion of syringes provided 
through NSPs and through pharmacy sales (note: 
pharmacy sales are measured separately and are 
different from pharmacy-based NSPs, which provide 
needles and syringes to IDUs free of charge and 
for the purpose of these indicators are included as 
NSPs). In addition, other modalities of delivery, such 
as vending machines or mobile van outlets48 might 
be employed as alternative and important providers 
of clean equipment. Countries might also include 
indicators for these modalities.
OST is effective in treating opioid dependence 
and also in preventing HIV among opioid injectors. 
However, in countries with considerable numbers 
of problematic non-opioid (e.g. ATS, cocaine and 
benzodiazepine) users, other drug dependence 
treatment options should be included as essential 
interventions. These other forms of drug depen-
dence treatment should be defined and described, 
and such treatments should be evidence-based 
(e.g. CBT23 and contingency management for ATS 
dependence).24
Indicators on availability measure whether an inter-
vention is available to the IDU population. For most 
of the interventions, a simple measure of the pres-
ence or absence of an intervention is determined. In 
the case of ART for IDUs, the presence of criteria 
excluding IDUs from accessing ART is noted. 
This simple measure of the presence of an inter-
vention may be supplemented by a measure of the 
extent of availability. For most of the interventions 
in this Guide, this is determined by calculating the 
number of sites offering the intervention per 1000 
IDUs. For example, in the case of NSPs, the indica-
tor is defined as follows:
Numerator:  Number of NSP sites 
Denominator:  (Number of IDUs)/1000
It is important to recognize that this measure pro-
vides only a crude indication of the extent of avail-
ability of an intervention – how well this level of 
availability “covers” a population of IDUs will be 
determined by the geographical distribution of both 
the services and the target population, and how eas-
ily accessible the services are for this group.
It is necessary to clearly define what is consid-
ered as a “site”. For example, the AIDS Projects 
Management Group considers distinct sites such as 
fixed sites or mobile units with a bus or a van as a 
single site; places where a mobile or outreach NSP 
stops are not considered as sites. Outreach teams 
are not sites except in the case where an outreach 
team is based in an office or clinic that is not oper-
ating as a fixed site. As discussed above, pharma-
cies are not counted as NSP sites unless they func-
tion as such by providing equipment free of charge. 
Pharmacies may be considered as sites of service 
delivery for other interventions, for example, if they 
dispense OST or ART, or if they provide HIV T&C or 
other relevant services. 
This indicator describes the general level of avail-
ability of this intervention relative to the size of the 
target population. However, it does not account for 
aspects that determine accessibility such as the 
geographical location of the service and how eas-
ily members of the target population can get to the 
service.
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3.4 Coverage of interventions
The term coverage can be used to decribe various 
aspects of reach and the effectiveness of interven-
tions.49 In this Guide, coverage is used to describe 
the extent to which an intervention is delivered to 
the target population, that is, the proportion of the 
target population in need of an intervention who are 
actually provided with it. 
Attempting to define coverage indicators poses 
many challenges. The denominator used in the mea-
sure of coverage of an intervention should be con-
sidered carefully. For example, available estimates 
of the number of IDUs in a country may not include 
people currently on treatment, which will impact 
on a measurement of what proportion of IDUs are 
reached by that treatment.
If coverage is defined as the number of individuals 
reached by an intervention, this could refer to any 
contact, rather than an effective contact. How often 
a person accesses a service is also important: an 
IDU reached once in a year by an NSP is qualitatively 
different from an IDU reached every day for a year 
by that NSP. In order to be effective, some inter-
ventions need near-daily reach, such as OST, while 
others such as T&C are not needed so frequently. 
Although subject to ongoing debate, current consen-
sus is that regular reach of an NSP should be consid-
ered as access at least once per month.
It is also important to distinguish between the num-
ber of clients accessing a service and the number 
of client contacts for that service. A common prob-
lem in data collection is that programmes record the 
number of contacts with clients and then confuse 
this with the number of clients reached. To measure 
regular reach (rather than the number of contacts), 
an anonymous system of recording return visits is 
necessary. A common method is to provide each cli-
ent with a unique identifier code (UIC). This enables 
a service to record patterns of attendance and, in 
particular, can reveal whether a client is reached 
regularly.50,51 This can be even more accurately 
measured if the same UIC is used across different 
services.
Another method of measuring the coverage of an 
NSP is to calculate the number of syringes distrib-
uted per IDU per year. Difficulties regarding how 
to count needles and syringes have been reported. 
Some commonly used syringes are 1 ml or 2 ml 
needle-and-syringe units, while others are syringes 
to which additional needles need to be fitted. Some 
countries report dramatically different numbers of 
needles and syringes distributed. In these circum-
stances, both numbers should be recorded.
3.5 Quality of interventions
Quality encompasses the scope, completeness, 
effectiveness, efficiency and safety of interventions. 
The quality of an intervention makes a vital differ-
ence to its impact on the epidemic.80 For example, 
OST programmes delivering low-dose methadone 
will be far less effective and have less impact than 
those delivering higher dosages. OST provided in 
combination with psychosocial support is more 
effective and will have a greater impact.13,52 
Assessment of quality is complex. However, here 
we propose relatively simple measures of whether 
quality standards are adhered to; that is, whether an 
intervention meets a defined standard. These qual-
ity standards can be set by UNODC/WHO/UNAIDS 
guidelines or by other authorities.53 
For OST, additional measures are proposed which 
examine the dose provided and duration of treat-
ment. The modalities and quality of drug depen-
dence treatment other than OST vary greatly. 
However, quality guidelines are available for these 
different drug dependence treatments. Good prac-
tice guidelines for different interventions may be 
accessed via Treatnet (www.unodc.org/treatment/
index.html).25
Quality guidelines for providing ART to IDUs, 
including recommended regimens that consider 
hepatotoxicity and drug–drug interactions, are also 
available.54 IEC delivered through well-structured 
outreach is an effective HIV prevention strategy.36 
Simple indicators are proposed in this Techinical 
guide. However,  recognizing the need to distribute 
new and varied materials and messages at regular 
intervals, more complex quality indicators could also 
be developed locally.
The quality of HIV/AIDS T&C is subject to current 
debate. Access to voluntary counselling and testing 
is an important part of HIV programmes in all set-
tings. WHO and UNAIDS have published guidelines 
on PITC,17,79 where it is recommended that in all epi-
demic settings, adults, adolsecents or children who 
present in clinical settings with signs and symptoms 
or medical conditions suggestive of HIV infection 
including TB be recommended PITC. In settings 
with generalized epidemics, T&C should be recom-
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mended to all those who present at a health facil-
ity. In concentrated and low-level epidemic settings, 
PITC could be offered at services for most-at-risk 
populations. WHO and UNODC are developing spe-
cific guidance for countries with concentrated epi-
demics among specific populations including IDUs. 
Some basic quality measures must ensure that HIV 
testing is voluntary, conducted with consent and 
includes counselling.18 In some countries, IDUs, 
particularly when in prison, are often compulsorily 
tested without consent. 
Another important aspect of quality is client satis-
faction or the user-friendliness of the intervention. 
This information can be gathered by conducting 
client surveys that assess clients’ satisfaction with 
staff and whether the services are available when 
needed, etc.
Programme staff who are well trained and sup-
ported improve the quality of programmes. Locally 
defined indictors that include this aspect could also 
be developed.
The operational characteristics of an intervention can 
have an important impact on the quality. For example, 
differences in the operational characteristics of NSPs, 
particularly restrictions on the number of syringes dis-
tributed per client, can impact effectiveness. It has 
been demonstrated that NSPs with less restrictive 
policies contribute to higher levels of coverage and 
lower levels of injection-related HIV risk behaviour.40 
3.6  Potential impact  
of interventions
This Technical guide is not primarily concerned with 
measuring the impact of interventions. However, 
basic impact data for each of the essential interven-
tions are extremely useful. 
HIV incidence gives the best indication of the impact 
of HIV prevention interventions but is generally diffi-
cult to collect. Mathematical modelling can be used 
to estimate HIV incidence.57 
It may take some time for data on HIV prevalence to 
reveal changes in infection risk, but these can be a 
useful indicator in the longer term. An understand-
ing and assessment of the surveillance system is 
necessary to allow for meaningful interpretation of 
the data; for example, increases in the number of 
IDUs could be the result of better sentinel surveil-
lance in this group; decreases could be the result 
of increased stigmatization and reluctance of IDUs 
to be tested. In addition, when access to HIV treat-
ment and care is available to IDUs, HIV prevalence 
can be seen to increase as the life expectancy of 
HIV-positive IDUs increases even if the incidence of 
HIV infection remains stable or decreases. 
Examples of guidelines for the delivery of different interventions:
◗ WHO. Chapter 5 - HIV/AIDS treatment and care for injecting drug users; Chapter 6 – Management of 
hepatitis C and HIV coinfection; Chapter 7 – Management of hepatitis B and HIV coinfection. In: HIV/AIDS 
treatment and care: clinical protocols for the WHO European Region. Copenhagen, WHO Regional Office 
for Europe, 2006.54 Available at: http://www.euro.who.int/Document/E90840.pdf
◗ WHO, UNAIDS, UNODC. A guide to starting and managing needle and syringe programmes. Geneva, 
WHO, 2007.51
◗ WHO. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. 
Geneva, WHO, (in press). Available at: http://www.who.int/substance_abuse/en/index.html 55 
◗ WHO. Operational guidelines for the management of opioid dependence in the South-East Asia Region. 
New Delhi, WHO Regional Office for South-East Asia, 2008. Available at: http://www.who.int/hiv/topics/
idu/drug_dependence/OSTguidelinesSEA.pdf 56 
◗ WHO, UNAIDS. Guidance on provider-initiated testing and counselling in health facilities. Geneva, 
WHO, 2007. Available at: http://whqlibdoc.who.int/publications/2007/9789241595568_eng.pdf17 
◗ WHO SEARO, WHO WPRO, UNODC. Guidance on testing and counselling for HIV in settings 
attended by people who inject drugs: improving access to treatment, care and prevention. Manila, 
WHO Regional Office for the Western Pacific, 2009 (in press).18
◗ UNAIDS. Practical guidelines for intensifying HIV prevention. Geneva, Switzerland, Joint United Nations 
Programme on HIV/AIDS, 2007.79
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Model projections suggest that HIV transmission can 
be reduced by interventions that reduce injecting fre-
quency and sharing. Case studies suggest that high 
coverage of HIV prevention interventions for IDUs 
may avert or delay potential HIV epidemics among 
IDUs and their spread to the general population.58,81
In this Technical guide, additional impact indicators are 
proposed that examine changes in injecting-related 
behaviours such as sharing of injecting equipment 
and frequency of injecting. These impact indicators 
are listed in the Guide under different interventions. 
It is important to recognize, however, that observed 
changes in these behaviours will invariably be due to 
multiple factors and a combination of interventions. 
In most cases, observed changes are unlikely to be 
attributable to a single isolated intervention. 
3.7 Data sources
The data required for the indicators presented in 
this Technical guide can be gathered from multiple 
sources. In most countries, these data are not col-
lected by a single agency and in most cases are 
not centrally organized or collated. Having a single, 
national-level agency that is supported to collate and 
report national data on a regular basis is advantageous. 
Data collected by services – programme data – can 
be used to determine the number of occasions ser-
vice has been provided and the number of individu-
als in contact with a service. In the case of NSPs 
and condom programmes, this would mean the 
number of items distributed. It is recommended 
that a census date be set to determine the num-
ber of individuals in OST and other treatment pro-
grammes at a single point in time. Monitoring and 
evaluation of services can provide data for indi-
cators that measure the quality of interventions 
offered; for example, to assess whether appropri-
ate guidelines are followed. 
Behavioural surveillance surveys (BSS), such as 
the Family Health International (FHI) BSS, can 
be undertaken to provide information on HIV risk 
behaviours such as condom use and safe injecting 
practices, and are useful in measuring the impact 
of interventions. The FHI BSS59 is recommended. 
Sentinel surveillance of IDUs can be undertaken 
to monitor the prevalence of HIV infection among 
IDUs. 
Infectious disease registration systems may be able 
to provide data on registered cases of HIV, AIDS and 
viral hepatitis.
3.8  Setting targets
No universal formula for target-setting exists. 
Limited evidence is available to assist in defining 
minimum levels of coverage or thresholds required 
for interventions to achieve a desired impact. 
A plethora of factors can affect the extent of HIV risk 
behaviours and levels of HIV transmission among 
IDUs; these factors influence the minimum level of 
coverage required in a given context. For example, in 
settings with high levels of HIV among IDUs, higher 
levels of coverage with HIV prevention interventions 
such as NSPs are likely to be required.61 
Mathematical modelling has demonstrated that the 
earlier in an epidemic an intervention is introduced, 
the more effective it can be in controlling the spread 
of HIV. 
In order to set firm coverage-level targets, consid-
eration of these variables is required. This evidence 
may be difficult to collect but an absence of such 
data should not impede the response. Useful targets 
can be set by acknowledging that greater levels of 
coverage are clearly superior to lower levels. 
Reflecting on these difficulties and gaps, the indica-
tive target levels presented in this Technical guide 
are based on current expert consensus, and cover-
age levels achieved in those countries that have had 
the greatest impact on reducing or avoiding high lev-
els of HIV infection among IDUs. Different indicative 
targets, expressed as a range, are provided for each 
intervention.
In light of the indicative targets levels proposed in 
this Technical guide, countries should set their own 
targets for each intervention with reference to the 
situation in their country. Each country should agree 
Guidelines on gathering and interpreting sentinel surveillance data are available:
◗ UNAIDS, WHO Working Group on Global HIV/AIDS and STI Surveillance. Guidelines for second gen-
eration HIV surveillance: the next decade. Geneva, WHO, UNAIDS, 2000. Available at: www.who.int/
hiv/pub/surveillance/en/ (accessed on 31 December 2008).60
16 WHO, UNODC, UNAIDS TECHNICAL GUIDE  WHO DEPARTMENT OF HIV/AIDS  17
on a credible measure of the target population and 
decide on ambitious but realistic targets for the 
interventions of the package. The targets selected 
should allow programmes to know whether they are 
making a difference to the epidemic, with the lower 
ranges having less of an impact on the epidemic 
than the higher ranges.
Target-setting for NSP coverage
The challenges in determining target levels for coverage of NSPs illustrates the complexity around the 
task of target-setting, given the current state of evidence available. There is no level of coverage that has 
been universally agreed upon as sufficient for all situations. Some have suggested that NSP coverage 
rates of 20–33% are sufficient;49 others have suggested that “high coverage sites” are those where 50% 
of IDUs have been reached by one or more HIV prevention programmes.6 
Some authorities recommend that IDUs should use a new sterile needle and syringe for every injection.43 
This requires knowledge of the frequency of injection, which is likely to vary between IDUs; in particular, 
between IDUs who inject different substances. For example, some studies have found that IDUs who 
use heroin inject more frequently than ATS injectors, while others have found that in some instances, for 
example, during binge use, ATS users inject more frequently.62–64
Some researchers have defined coverage as being the number of syringes obtained by a client in a 
month measured against the number of injections in that month self-reported by that client.40,65 They 
have observed that distribution of more than one syringe per injection per injector actually conferred the 
greatest benefit.65 
In contrast, mathematical modelling57,61 and observational studies in developed countries,66 which have 
examined the impact of NSPs on HIV transmission, have suggested that the distribution of fewer syringes 
than the equivalent of “one syringe per injection” can still reduce HIV transmission rates. These lower 
coverage levels are thought to have been effective because other conditions were in place, namely, suf-
ficient breadth of programmes available; sufficient quality of programmes and sufficient credible educa-
tion delivered regularly. In the case of some countries, such as Australia and the United Kingdom, HIV 
prevention programmes, including NSPs, were also introduced aggressively at an early stage of the HIV 
epidemic among IDUs with the result that background HIV prevalence rates remained relatively low.
It is important to recognize that other contextual factors and behaviours also influence HIV transmission 
and will therefore have a bearing on the NSP coverage levels needed. For example, reusing a syringe 
after another person has used it is clearly more risky than a person reusing a syringe that only he or she 
has used. In each of these two cases, education around reusing injecting equipment may have different 
impacts upon HIV prevention. Lower levels of NSP coverage may be sufficient to sustain an effective 
response to HIV prevention if clean injecting equipment is also available from other sources, such as 
pharmacies, from other injectors, or purchasing them from street dealers. The type of drug being injected 
may also affect the extent of injecting risk and have implications for the coverage levels required. For 
example, some comparisons of the level of injecting risk between ATS injectors and those injecting other 
drugs have found greater sharing of equipment among ATS than heroin injectors.67,68 In other sites no such 
differences were found.62
16 WHO, UNODC, UNAIDS TECHNICAL GUIDE  WHO DEPARTMENT OF HIV/AIDS  17
3.9  Next steps:  
after setting targets
Once targets have been set, they need to be opera-
tionalized and monitored. This requires an opera-
tional plan and a monitoring and evaluation frame-
work based on these targets. 
THE TARGET-SETTING PROCESS
Examples of target-setting in the field69
Two UNODC/WHO Technical Consultations on Setting Targets for Universal Access to HIV Prevention 
Treatment and Care for Injecting Drug Users in Estonia, Latvia, Lithuania and Poland (Vilnius, Lithuania, 23 
March 2007) and Central Asia and Azerbaijan (Tashkent, Uzbekistan, 28–30 May 2007) contributed to the 
development and field-testing of this Technical guide.
Denominator populations of IDUs were available for most of the countries involved in the field-testing; 
however, the quality of these data was variable. Availability of services varied considerably – for example, 
in some Central Asian countries, OST had not yet been introduced. In many countries access was limited, 
for example, by geographical location (in many countries essential interventions were available only in the 
major cities and/or unavailable in hard-to-reach locations such as prisons); affordability (for example, in 
some countries patients were expected to pay for OST or other ancillary services); equity and discrimina-
tion (most countries had exclusion criteria other than medical ones, e.g. OST was limited to those above 
a certain age or to those IDUs who are HIV-infected or who have “failed” other drug dependence treat-
ment); and rationing (supply of services was limited by cost or other considerations and not determined by 
need). The quality of the programmes was also variable and many programmes in this region are rooted 
in a philosophy and approach geared towards abstinence from drug use.
Field-testing of this Guide revealed the value of discussing and reaching a national consensus on targets in 
the wide range of interventions that comprise the comprehensive package. Overall, there is a tendency to 
select realistic and achievable targets that fall short of the levels necessary to have an impact on the HIV 
epidemic. For example, the current coverage of OST in three countries varied between 2% and 5%, rated 
as “low-level coverage” but the planned coverage targets ranged between 7% and 20% by 2010, which 
can at best be rated as “medium-level coverage”. The targets for NSPs were much more ambitious, rang-
ing between 5% and 40% in 2007 with very ambitious targets for 2010 ranging between 25% for one and 
60% for four other countries. The last target is rated as “high-level coverage”. The discrepancy between 
the targets for these two interventions in these countries may be explained by the different supportive 
environments, with more political support for implementation and scaling up of NSPs than for OST.
Guidance on operationalization, and monitoring and evaluation of interventions is outside the 
scope of this Guide but can be found in the following documents:
◗ WHO. Guide to starting and managing needle and syringe programmes. Geneva, WHO, 2007. Available 
at: http://www.who.int/hiv/idu/Guide_to_Starting_and_Managing_NSP.pdf51  
◗ WHO. Guidelines for psychosocially-assisted pharmacotherapy for the management of opioid depen-
dence. Geneva, WHO, (in press).55
◗ UNODC. Drug abuse treatment and rehabilitation: a practical planning and implementation guide. 
Vienna, UNODC, 2003.70  Available at: http://www.unodc.org/pdf/report_2003-07-17_1.pdf
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Although primarily for national target-setting, 
the Guide will also be useful in setting targets for 
regions in large countries. The geographical scope 
should be determined and made explicit. 
4. Framework for setting  
indicators and indicative targets
4.1 Needle and syringe programmes (NSPs)
Availability
4.1.1 Do NSPs (including pharmacy sites providing no-cost needles and syringes) exist?
Response: Yes/No
4.1.2 Are pharmacy sales of needles and syringes available? 
Response: Yes/No
4.1.3 NSP sites (including pharmacy sites providing no-cost needles and syringes) per 1000 IDUs
Data source: Programme data 
Numerator: Number of NSP sites (including pharmacy sites providing  
 no-cost needles and syringes)
Denominator:  (Number of IDUs)/1000
Target: Context-specific (should consider geographical distribution of the  
 target population and other local factors influencing accessibility)
4.1.4 Pharmacy sales sites per 1000 IDUs
Data source: Programme data
Numerator: Number of pharmacy sites selling syringes
Denominator:  (Number of IDUs)/1000
Target: Context-specific (should consider geographical distribution of the  
 target population and other local factors influencing accessibility)
Coverage
Three coverage indicators are presented. The availability of data may dictate which of these indicators can 
be measured.
4.1.5 Percentage of IDUs regularly reached by NSPs
Data source: Programme data
Numerator: Number of IDUs who accessed an NSP once per month  
 or more in the past 12 months
Denominator:  Number of IDUs
Targets: Low: <20%
 Medium: >20– <60%
 High: >60%
Comment: The numerator should count individual clients and not the number  
 of contacts or occasions of service recorded by NSP services.
 The high target level is based on a retrospective analysis of the  
 coverage required to reverse the HIV/AIDS epidemic among IDUs  
 in New York71
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4.1.6 Percentage of IDUs reached by NSPs in the past month
Data source: Programme data
Numerator: Number of IDUs who accessed an NSP in the past 1 month
Denominator:  Number of IDUs
Targets: Low: <20%
 Medium: >20– <60%
 High: >60%
Comment: The numerator should count individual clients and not the number  
 of contacts or occasions of service recorded by NSP services. 
4.1.7 Syringes distributed per IDU per year
Data source: Programme data
Numerator:  Number of syringes distributed in the past 12 months
Denominator: Number of IDUs
Targets: Low: <100 per IDU per year 
 Medium: >100–<200
 High: >200
Comment:  These levels are based upon studies in developed country settings 
 investigating the levels of syringe distribution and impact on HIV  
 transmission.57,66 Note that the levels required for the prevention 
 of HCV are likely to be much higher than those presented here. 
 In most cases only data on the number of syringes distributed via  
 NSPs but not pharmacy sales will be available.
Quality
4.1.8 Percentage of NSP sites  adhering to WHO guidelines on NSP51
Data source: Programme monitoring and evaluation 
Numerator: Number of NSP sites adhering to WHO guidelines51
Denominator:  Number of NSP sites
Targets: Low: <50%
 Medium: >50–<80%
 High: >80%
4.1.9 Percentage of NSP sites adhering to UNAIDS best practice recommendations  
for HIV prevention among IDUs6 
Data source: Programme monitoring and evaluation 
Numerator: Number of NSP sites adhering to UNAIDS best practice guidelines6 
Denominator:  Number of NSP sites
Targets: Low: <50%
 Medium: >50–<80%
 High: >80%
4.1.10 Percentage of occasions when clients access an NSP and receive IEC
Data source: Programme data 
Numerator: Number of occasions when clients access an NSP and receive IEC  
 (i.e. the number of client contact events at an NSP that involve  
 the client receiving IEC)
Denominator:  Total number of NSP occasions of service 
Targets: Low: <20%
 Medium: >20–<40%
 High: >40%
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4.1.11 Percentage of occasions when clients access an NSP and receive condoms 
Data source: Programme data 
Numerator: Number of occasions when clients access an NSP and receive  
 condoms (i.e. the number of client contact events at an NSP  
 that involve the client receiving condoms)
Denominator:  Total number of NSP occasions of services
Targets: Low: <20%
 Medium: >20–<40%
 High: >40%
Potential impact indicators
4.1.12 Increase in percentage of IDUs reporting the use of sterile injecting equipment  
the last time they injected
Data source: Behavioural surveillance surveys (e.g. FHI BSS for IDUs). This indicator 
 is also a core indicator of the UNGASS on the HIV reporting process  
 for monitoring the Declaration of Commitment on HIV/AIDS7
Numerator: Number of respondents reporting the use of sterile injecting  
 equipment the last time they injected drugs
Denominator:  Number of respondents who report having injected in the past month
4.1.13 Reduction in prevalence of HIV among IDUs
Data source: HIV sentinel surveillance among IDUs
Numerator: Number of IDUs with HIV in sample
Denominator:  Number of IDUs in sample
4.2 Drug dependence treatment 
4.2a Opioid substitution therapy (OST)
OST is available in many forms; the most commonly used are methadone and/or buprenorphine. In countries 
where a range of substitution medications are used, all of them should be included when measuring these 
indicators. OST for non-injecting opioid-dependent people is also considered in this Guide as transition to 
injecting among this group is not uncommon72 and hence treatment for opioid dependence reduces the likeli-
hood of initiation to injecting and can be considered an HIV prevention strategy. 
Availability
4.2a.1 Is OST available? 
Response: Yes/No
4.2a.2 OST sites per 1000 opioid injectors
Data source: Programme data 
Numerator: Number of OST sites 
Denominator:  (Number of opioid injectors)/1000
Target: Context-specific (should consider geographical distribution of the 
 target population and other local factors influencing accessibility)
4.2a.3 OST sites per 1000 opioid-dependent people
Data source: Programme data 
Numerator: Number of OST sites 
Denominator:  (Number of opioid-dependent people including injectors and  
 non-injectors)/1000
Target: Context-specific (should consider geographical distribution of the  
 target population and other local factors influencing accessibility)
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Coverage
4.2a.4 Percentage of opioid-dependent people on OST at census date
Data source: Programme data 
Numerator: Number of people on OST at census date
Denominator:  Number of opioid-dependent people (including both injectors  
 and non-injectors)
Target: Low: <20%
 Medium: <20–<40%  
 High: >40% 
Comment: High target level based on levels of coverage achieved  
 in countries with well-established OST programmes 
4.2a.5  Ratio of number of people on OST against number of opioid injectors
Data source: Programme data 
Numerator: Number of people on OST at census date
Denominator:  Number of opioid injectors
Targets: Low: <0.2
 Medium: <0.2–<0.4  
 High: >0.4 
Comment: High target level based on levels of coverage achieved  
 in countries with well-established OST programmes
  
4.2a.6  Percentage of opioid injectors on OST
Data source: Programme data 
Numerator: Number of IDUs on OST at census date
Denominator:  Number of opioid injectors  
Targets: Low: <20% 
 Medium: <20–<40%  
 High: >40% 
Comment: High target level based on levels of coverage achieved  
 in countries with well-established OST programmes
Quality
4.2a.7  Percentage of OST sites adhering to WHO guidelines55,56 
Data source: Programme monitoring and evaluation 
Numerator: Number of OST sites adhering to WHO guidelines55,56 
Denominator:  Number of OST sites
Targets: Low: <50%
 Medium: >50–<80%
 High: >80%
4.2a.8  Percentage of OST programmes providing psychosocial support 
Data source: Programme monitoring and evaluation 
Numerator: Number of OST sites/programmes offering psychosocial support  
 to all OST patients
Denominator:  Number of OST sites/programmes
Targets: Low: <50%
 Medium: >50–<80%
 High: >80%
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4.2a.9  Percentage of patients in OST receiving recommended maintenance dose 
Data source: Programme data 
Numerator:  Number of patients on OST who receive a maintenance  
 dose >60 mg of methadone or 12 mg of buprenorphine
Denominator:  Number of patients on OST at census date
Targets: Low: <50%
 Medium: >50–<80%
 High: >80%
Comment:  Evidence suggests that maintenance doses of 60–120 mg  
 methadone or 12–24 mg buprenorphine are optimal.55
 
4.2a.10  Percentage of individuals currently on OST who have been on OST  
continuously for the past 12 months
Data source: Programme data 
Numerator: Number of individuals completing at least 6 months  
 of continuous treatment on OST in the past 12 months
Denominator:  Number of OST treatment slots at census date
Targets: Low: <50%
 Medium: >50–<80%
 High: >80%
Comment:  Evidence suggests that >6 months’ duration of OST is optimal.55
4.2a.11 Average duration of treatment on OST
Data source: Programme data 
Target: 6 months or longer
4.2a.12 Average maintenance dose of OST
Data source: Programme data 
Targets: 60 mg of methadone per day or 12 mg of buprenorphine 
Potential impact indicators
4.2a.13 Percentage of IDUs receiving OST reporting the use of sterile injecting equipment  
the last time they injected
Data source: Behavioural surveillance surveys (e.g. FHI BSS for IDUs)
Numerator: Number of respondents who report using sterile injecting  
 equipment the last time they injected drugs
Denominator: Number of respondents currently receiving OST who report  
 having injected in the past month
Comment: This measure provides an indication of the impact of this  
 intervention on those receiving it. While it is listed as an  
 “impact indicator” it could also be considered as an indicator  
 to assess the quality of the intervention. 
4.2a.14 Reduction in the frequency of injection 
Data source: Behavioural surveillance surveys (e.g. FHI BSS for IDUs)
Numerator: Number of IDUs injecting once per day or more 
Denominator:  Number of IDUs receiving OST in sample 
Or alternatively:
Data source: Behavioural surveillance surveys (e.g. FHI BSS for IDUs)
Numerator: Mean number of injections per IDU per week
Sample: IDUs receiving OST 
Comment: These measures provide an indication of the impact of this  
 intervention on those receiving it. While they are listed as  
 “impact” indicators they could also be considered as indicators to  
 assess the quality of the intervention. 
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4.2a.15 Reduction in prevalence of HIV among IDUs
Data source: HIV sentinel surveillance among IDUs
Numerator: Number of IDUs in sample testing positive for HIV
Denominator:  Number of IDUs in sample
4.2b. Other drug dependence treatment
Availability
4.2b.1 Which of the following drug dependence interventions are available? 
a) Drug detoxification services (includes inpatient and outpatient services but does not 
include compulsory or forced detoxification)
b) Rehabilitation programmes (includes inpatient and outpatient services but does not 
include compulsory or forced rehabilitation)
c) CBT 
d) Contingency management 
e) Psychosocial support and counselling 
f) Peer-based support groups (e.g. Narcotics Anonymous)
g) Other interventions – these should be specified
4.2b.2 Treatment sites per 1000 IDUs
Data source: Programme data 
Numerator: Number of sites offering each intervention 
Denominator:  (Number of IDUs)/1000
Target: Context-specific (should consider geographical distribution of  
 the target population and other local factors influencing accessibility)
Coverage
4.2b.3  Ratio of IDUs on treatment 
Data source:  Programme data
Numerator: Number of IDUs on specified treatment/intervention at census date
Denominator:  Number of IDUs
Targets: Low: <0.1
 Medium: >0.1–<0.3
 High: >0.3
Quality
4.2b.4  Percentage of treatment sites adhering to recognized guidelines70 
Data source: Programme monitoring and evaluation 
Numerator: Number of treatment sites adhering to recognized guidelines70 
Denominator:  Number of treatment sites
Targets: Low: <50%
 Medium: >50–<80%
 High: >80%
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4.2b.5 Percentage of individuals in voluntary rather than compulsory treatment 
Data source: Programme monitoring and evaluation 
Numerator: Number of individuals on non-compulsory treatment 
Denominator:  Number of individuals on treatment
Targets: 100% voluntary treatment is desirable
Comment: The numerator should include all those on voluntary treatment. 
Individuals who are under a compulsory treatment order (for exam-
ple, those diverted to compulsory treatment in the community 
as an alternative to incarceration) should also be included in the 
numerator as should prisoners who are receiving treatment while 
in prison. Individuals who have been incarcerated for the purpose 
of treatment, for example, in compulsory treatment camps, should 
not be included in the numerator.
Potential impact indicators
4.2b.6 Percentage of IDUs receiving non-OST treatment reporting the use of sterile injecting  
equipment the last time they injected
Data source: Behavioural surveillance surveys (e.g. FHI BSS for IDUs)
Numerator: Number of respondents who report using sterile injecting  
 equipment the last time they injected drugs
Denominator: Number of respondents receiving the intervention who report  
 having injected in the past month
Comment: This measure provides an indication of the impact of this  
 intervention on those receiving it. While it is listed as an “impact  
 indicator” it could also be considered as an indicator to assess the  
 quality of the intervention. 
 4.2b.7  Reduction in the frequency of injecting 
Data source: Behavioural surveillance surveys (e.g. FHI BSS for IDUs)
Numerator: Number of IDUs injecting once per day or more 
Denominator:     Number of IDUs receiving intervention in sample 
Or alternatively:
Data source: Behavioural surveillance surveys (e.g. FHI BSS for IDUs)
Numerator: Mean number of injections per IDU per week
Sample: IDUs receiving intervention
Comment: These measures provide an indication of the impact of this  
 intervention on those receiving it. While they are listed as “impact”  
 indicators they could also be considered as indicators that assess  
 the quality of the intervention. 
4.2b.8 Reduction in the prevalence of HIV among IDUs
Data source: HIV sentinel surveillance among IDUs
Numerator: Number of IDUs in the sample testing HIV-positive
Denominator:  Number of IDUs in the sample
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4.3 HIV testing and counselling (T&C) 
Availability
4.3.1 Is T&C available for IDUs? 
Response: Yes/No
4.3.2 T&C sites per 1000 IDUs
Data source: Programme data 
Numerator: Number of sites offering T&C for IDUs
Denominator:  (Number of IDUs)/1000
Target: Context-specific (should consider geographical distribution  
 of the target population and other local factors influencing accessibility)
Coverage
4.3.3 Percentage of IDUs who received an HIV test in the past 12 months and know the results 
Data source: Behavioural surveillance surveys (e.g. FHI BSS for IDUs).  
 This indicator is also a core indicator of the UNGASS on the HIV  
 reporting process for monitoring the Declaration of Commitment 
 on HIV/AIDS.7
Numerator: Number of IDUs in the sample tested for HIV during  
 the past 12 months and who know their results 
Denominator:  Number of IDUs in the sample
Or alternatively:
Data source: Programme data
Numerator: Number of IDUs who have been tested for HIV during  
 the past 12 months and who received the results 
Denominator:  Number of IDUs in the sample
Targets: Low: <40%
 Medium: >40–<75%
 High: >75%
Quality
4.3.4 Percentage of sites adhering to WHO guidelines on T&C17,18 
Data source: Programme monitoring and evaluation 
Numerator: Number of sites offering T&C and adhering to WHO guidelines17,18 
Denominator:  Number of T&C sites
Targets: Low: <50%
 Medium: >50–<80%
 High: >80%
Comment: The delivery of HIV/AIDS T&C is subject to current debate. 
WHO and UNAIDS have published guidelines on PITC, where 
it is recommended that countries with generalized epidemics 
offer T&C to all who attend health facilities (WHO/UNAIDS PITC 
Guidelines ).17 WHO and UNODC are developing specific guidance 
for countries with concentrated epidemics among specific popula-
tions including IDUs. Some basic quality measures must ensure 
that HIV testing is voluntary, conducted with consent and includes 
counselling. In some countries, IDUs, particularly when in prison, 
are often compulsorily tested without consent.
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Potential impact indicators
4.3.5 Increase in percentage of IDUs aware of their HIV status
Data source: Behavioural surveillance surveys (e.g. FHI BSS for IDUs) that  
 include HIV testing of participants
Numerator: Number of participants who were aware of their status confirmed  
 by testing
Denominator: Number of participants 
4.3.6 Increase in percentage of IDUs testing HIV-positive referred and assessed for ART
Data source: Programme data 
Numerator: Number of IDUs testing HIV-positive referred and assessed for ART
Denominator: Number of IDUs testing HIV-positive 
4.4 Antiretroviral therapy (ART)
Availability
4.4.1  Is ART available to people who are active IDUs (i.e. being an active IDU is not  
an exclusion criterion for receiving ART)? 
Response: Yes/No
Coverage
4.4.2 Percentage of HIV-positive IDUs receiving ART
Data source: Programme data; HIV prevalence data
Numerator: Number of IDUs receiving ART
Denominator:  Number of HIV-positive IDUs for whom ART is indicated
Targets: Low: <25%
 Medium: >25–<75%
 High: >75%
Comment: Some programme data or registration systems for ART may not 
indicate whether a patient receiving ART is an IDU so alternative 
data sources may be required to determine the numerator.
It is desirable to determine the number of HIV-positive IDUs requir-
ing ART. However, if this information is not available, the number 
of all HIV-positive IDUs could be used instead. It should also be 
noted that using HIV registration data is likely to underestimate of 
the number of HIV-positive IDUs, given that many HIV-positive IDUs 
may be undiagnosed. Estimating the number of HIV-positive IDUs 
using a measure of HIV prevalence among IDUs and an estimate of 
the total number of IDUs can also be problematic, given the uncer-
tainty of both the HIV prevalence and IDU estimates. A decision on 
which method to use to determine the denominator for this indica-
tor should consider the relative limitations of both methods and the 
data available in that particular country context. 
Indicative coverage targets for ART are subject to much debate. 
ART coverage of 100% is generally not feasible. The highest cover-
age achieved in high-income countries is 75–80% and therefore 
here coverage of over 75% is considered high-level coverage.
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4.4.3 Ratio of IDUs in receipt of ART
Data source: HIV registration data, ART programme data and treatment surveys
Numerator:  Number of IDUs receiving ART/total number receiving ART 
Denominator: Number of HIV-positive IDUs attributed to injecting drug  
 use/total number of HIV cases
Targets: >1 desirable
Comment: This indicator is a measure of the equity of access to ART for 
IDUs who are HIV-positive compared with that for all HIV-positive 
people. Commonly, IDUs have poorer levels of access to ART 
compared with non-IDUs, despite evidence that provision of ART 
to IDUs has population-wide health benefits and despite evidence 
that IDUs can successfully undergo treatment and benefit from 
ART.19–21
Quality
4.4.4 Percentage of sites adhering to WHO guidelines on ART54 
Data source: Programme monitoring and evaluation 
Numerator: Number of ART sites adhering to WHO guidelines on ART54
Denominator:  Number of ART sites
Targets: Low: <50%
 Medium: >50–<80%
 High: >80%
Potential impact indicators
4.4.5 Decreased AIDS cases and AIDS-related mortality among IDUs
Data source: HIV/AIDS register data 
Indicator: a) Number of AIDS cases among HIV-positive IDUs
 b) Number of AIDS-related deaths among IDUs 
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4.5 Prevention and treatment of sexually transmitted 
infections (STIs) 
Sexual health services for IDUs may be provided by organizations or services that offer a number of services 
to IDUs or by mainstream sexual health services that can be accessed by IDUs. It may be difficult to gather 
data on IDUs accessing mainstream sexual health services as these services may not collect data on the 
status of injecting drug use among their clients.
Availability
4.5.1 Are there sites offering STI screening and treatment for IDUs?
Response: Yes/No
4.5.2 STI intervention sites per 1000 IDUs
Data source: Programme data 
Numerator: Number of sites offering STI screening and treatment to IDUs
Denominator:  (Number of IDUs)/1000
Target: Context-specific (should consider geographical distribution  
 of the target population and other local factors influencing accessibility)
Coverage
4.5.3 Percentage of IDUs screened for STIs in the past 12 months 
Data source: Programme data
Numerator: Number of IDUs screened in the past 12 months
Denominator:  Number of IDUs
Or alternatively
Data source: BSS with questions on exposure to interventions
Numerator: Number of IDUs screened in the past 12 months
Denominator:  Number of IDUs in sample
Targets: Low: <20%
 Medium: >20–<50% 
 High: >50% 
Quality
4.5.4 Percentage of sites adhering to WHO guidelines on STI screening and treatment73 
Data source: Programme monitoring and evaluation 
Numerator: Number of STI intervention sites adhering to WHO guidelines73
Denominator:  Number of STI intervention sites
Targets: Low: <50%
 Medium: >50–<80%
 High: >80%
4.5.5 Percentage of IDUs diagnosed with STI who received treatment
Data source: Programme data 
Numerator: Number of IDUs receiving STI treatment in the past 12 months
Denominator:  Number of IDUs diagnosed with an STI in the past 12 months 
Targets: Low: <50%
 Medium: >50–<80%
 High: >80%
28 WHO, UNODC, UNAIDS TECHNICAL GUIDE  WHO DEPARTMENT OF HIV/AIDS  29
FRAMEWORK FOR SETTING INDICATORS AND INDICATIVE TARGETS
Potential impact indicators
4.5.6 Decrease in the number of STIs
Data source: Programme data
Numerator: Number of IDUs diagnosed with an STI in the past 12 months
Denominator:  Number of IDUs tested for STI in the past 12 months
Or alternatively
Data source:  BSS
Numerator:  Number of IDUs who self-reported symptoms of an STI  
 in the past 12 months
Denominator:  Number of participants who reported that they had sexual  
 intercourse in the past 12 months 
4.6 Condom programmes for IDUs and their sexual partners
Availability
4.6.1 Are there condom distribution programmes targeting IDUs and their sexual partners?
 Response: Yes/No
4.6.2 Condom programme outlets per 1000 IDUs
Data source: Programme data 
Numerator: Number of condom programme sites 
Denominator:  (Number of IDUs)/1000
Target: Context-specific (should consider geographical distribution  
 of the target population and other local factors influencing accessibility)
Comment: Condom programme outlets include those where condoms 
 are available free of charge. 
Coverage
4.6.3 Free condoms distributed each year per IDU 
Data source: Programme data
Numerator: Number of free condoms distributed in the past 12 months
Denominator:  Number of IDUs
Targets: Low: <50%
 Medium: >50–<100%
 High: >100%
Quality
4.6.4 Percentage of condom programme distribution sites adhering to UNFPA guidelines74,75
Data source: Programme monitoring and evaluation 
Numerator: Number of condom programme sites adhering  
 to UNFPA guidelines74,75
Denominator:  Number of STI intervention sites
Targets: Low: <50%
 Medium: >50–<80%
 High: >80%
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Potential impact indicators
4.6.5 Increase in the percentage of IDUs reporting the use of a condom the last time 
 they had sexual intercourse
Data source:  BSS (e.g. FHI BSS for IDUs). This indicator is also a core indicator  
 of the UNGASS on the HIV reporting process for monitoring the  
 Declaration of Commitment on HIV/AIDS7
Numerator: Number of respondents who reported that a condom was used  
 the last time they had sex
Denominator: Number of respondents who reported having had sexual  
 intercourse in the past month 
4.6.6 Decrease in the number of STIs
Data source: Programme data
Numerator: Number of IDUs diagnosed with an STI in the past 12 months
Denominator:  Number of IDUs tested for STI in the past 12 months
Or alternatively
Data source:  BSS
Numerator:  Number of IDUs who self-reported symptoms of an STI  
 in the past 12 months
Denominator:  Number of participants who reported having had sexual  
 intercourse in the past 12 months
4.7 Targeted information, education and communication 
(IEC) for IDUs and their sexual partners
Availability
4.7.1  Is targeted IEC for IDUs available?
Response: Yes/No
4.7.2 Number of sites offering targeted IEC for IDUs per 1000 IDUs
Data source: Programme data 
Numerator: Number of sites offering targeted IEC for IDUs
Denominator:  (Number of IDUs)/1000
Target: Context-specific (should consider geographical distribution  
 of the target population and other local factors influencing accessibility)
4.7.3 Percentage of sites accessed by IDUs offering targeted IEC for IDUs
Data source: Programme data 
Numerator: Number of NSP sites, drug treatment sites and sexual health  
 services for IDUs offering targeted IEC for IDUs
Denominator:  Number of NSP sites, drug treatment sites and sexual health  
 services for IDUs
Targets: Low: <50%
 Medium: >50–<90%
 High: >90%
4.7.4 Number of different targeted materials on injecting drug use distributed per IDU per year
Data source: Programme data 
Numerator: Number of targeted materials on injecting drug use distributed  
 in the past 12 months
Denominator:  Number of IDUs
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Coverage
4.7.5 Percentage of IDUs reached by IEC
Data source: Programme data
Numerator: Number of IDUs who received IEC in the past 12 months
Denominator:  Number of IDUs
Targets: Low: <50%
 Medium: >50–<90%
 High: >90%
4.7.6 Percentage of occasions when clients accessed an NSP and received IEC 
Data source: Programme data 
Numerator: Number of occasions when clients accessed an NSP and received  
 IEC (i.e. the number of client contact events at an NSP that 
  involved the client receiving IEC)
Denominator:  Total number of NSP occasions of services
Targets: Low: <20%
 Medium: >20–<40%
 High: >40%
Quality
4.7.7 Percentage of sites adhering to WHO guidelines on targeted IEC for IDUs51 
Data source: Programme monitoring and evaluation 
Numerator: Number of sites adhering to WHO guidelines51 
Denominator:  Number of sites offering targeted IEC for IDUs 
Targets: Low: <50%
 Medium: >50–<80%
 High: >80%
Potential impact indicators
4.7.8 Increase in the percentage of IDUs reporting the use of sterile injecting equipment  
the last time they injected
Data source: BSS (e.g. FHI BSS for IDUs). This indicator is also a core indicator  
 of the UNGASS on the HIV reporting process for monitoring the  
 Declaration of Commitment on HIV/AIDS7
Numerator: Number of respondents who reported using sterile injecting  
 equipment the last time they injected drugs
Denominator: Number of respondents who reported having injected in the  
 past month
4.7.9 Increase in the percentage of IDUs who both correctly indentify ways of preventing the 
sexual transmission of HIV and who reject major misconceptions about HIV transmission
Data source: BSS (e.g. FHI BSS for IDUs). This indicator is also a core indicator  
 of the UNGASS on the HIV reporting process for monitoring the  
 Declaration of Commitment on HIV/AIDS7
Numerator: Number of IDUs in sample with HIV
Denominator:  Number of IDUs in sample
FRAMEWORK FOR SETTING INDICATORS AND INDICATIVE TARGETS
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4.8 Diagnosis and treatment of and vaccination  
for viral hepatitis 
Availability
4.8.1 Is HAV vaccination available for IDUs?
Response: Yes/No
Comment: Programmes may vary depending upon the prevalence of HBV and HAV.
4.8.2 Is HBV vaccination available for IDUs?
Response: Yes/No
Comment: Programmes may vary depending upon the prevalence of HBV  
 and HAV.
4.8.3 Is HCV treatment available for IDUs?
Response: Yes/No
Comment: Hepatitis C treatment is expensive and currently not available  
 in many countries.
4.8.4 Is HBV treatment available for IDUs?
Response: Yes/No
4.8.5 Number of sites offering HBV vaccination for IDUs per 1000 IDUs
Data source: Programme data 
Numerator: Number of sites offering targeted HBV vaccination for IDUs
Denominator:  (Number of IDUs)/1000
Target: Context-specific (should consider geographical distribution of the  
 target population and other local factors influencing accessibility)
4.8.6 Number of sites offering HAV vaccination for IDUs per 1000 IDUs
Data source: Programme data 
Numerator: Number of sites offering targeted HAV vaccination for IDUs
Denominator:  (Number of IDUs)/1000
Target: Context-specific (should consider geographical distribution of the 
 target population and other local factors influencing accessibility)
4.8.7 Number of sites offering HCV treatment for IDUs per 1000 IDUs
Data source: Programme data 
Numerator: Number of sites offering targeted HCV treatment for IDUs
Denominator:  (Number of IDUs)/1000
Target: Context-specific (should consider geographical distribution of the  
 target population and other local factors influencing accessibility)
4.8.8 Number of sites offering HBV treatment for IDUs per 1000 IDUs
Data source: Programme data 
Numerator: Number of sites offering targeted HBV treatment for IDUs
Denominator:  (Number of IDUs)/1000
Target: Context-specific (should consider geographical distribution of the  
 target population and other local factors influencing accessibility)
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Coverage
4.8.9 Percentage of IDUs referred for HBV vaccination
Data source: Programme data
Numerator: Number of IDUs referred for HBV vaccination in the past 12 months
Denominator:  Number of IDUs
Targets: Low: <20%
 Medium: >20–<40%
 High: >40%
4.8.10 Percentage of IDUs completing course of HBV vaccination
Data source: Programme data
Numerator: Number of IDUs who, in the past 12 months,  
 completed the course of HBV vaccination
Denominator:  Number of IDUs who were due to complete course  
 of HBV vaccination in the past 12 months
Targets: Low: <30%
 Medium: >30–<60%
 High: >60%
4.8.11 Percentage of IDUs diagnosed with and receiving treatment for HBV
Data source: Programme data
Numerator: Number of IDUs diagnosed with and receiving treatment  
 for HBV in the past 12 months
Denominator:  Number of IDUs diagnosed HBV-positive and requiring  
 treatment in the past 12 months
Targets: Low: <50%
 Medium: >50–<80%
 High: >80%
4.8.12 Percentage of IDUs completing treatment for HBV
Data source: Programme data
Numerator: Number of IDUs completing HBV treatment in the past 12 months
Denominator:  Number of IDUs who were due to complete HBV treatment  
 in the past 12 months
Targets: Low: <30%
 Medium: >30–<60%
 High: >60%
4.8.13 Percentage of HCV-positive IDUs receiving treatment for HCV
Data source: Programme data
Numerator: Number of IDUs receiving treatment for HCV in the past 12 months
Denominator:  Number of HCV-positive IDUs
Targets: Low: <5%
 Medium: >10–<15%
 High: >15%
4.8.14 Percentage of IDUs completing treatment for HCV
Data source: Programme data
Numerator: Number of IDUs completing HCV treatment in the past 12 months
Denominator:  Number of IDUs who were due to complete HCV treatment  
 in the past 12 months
Targets: Low: <30%
 Medium: >30–<60%
 High: >60%
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Quality
4.8.15 Percentage of sites adhering to guidelines on HAV/HBV vaccination
Data source: Programme monitoring and evaluation 
Numerator: Number of sites offering HAV/HBV vaccination and adhering  
 to relevant national and international guidelines (such as Prevention of  
 hepatitis A,B and C and other hepatotoxic factors in people  
 living with HIV; Clinical protocols for the WHO European Region, 
 chapter 854)
Denominator:  Number of sites offering HAV/HBV vaccination
Targets: Low: <50%
 Medium: >50–<80%
 High: >80%
4.8.12 Percentage of sites adhering to guidelines on HBV treatment 
Data source: Programme monitoring and evaluation 
Numerator: Number of sites offering HBV treatment and adhering to relevant  
 national or other guidelines (such as Management of hepatitis B  
 and HIV coinfection; Clinical protocols for the WHO European 
 Region, chapter 754)
Denominator:  Number of sites offering HBV treatment
Targets: Low: <50%
 Medium: >50–<80%
 High: >80%
4.8.13 Percentage of sites adhering to guidelines on HCV treatment 
Data source: Programme monitoring and evaluation 
Numerator: Number of sites offering HCV treatment and adhering to relevant  
 national or other guidelines (such as Management of hepatitis C  
 and HIV coinfection; Clinical protocols for the WHO European 
 Region, chapter 654)
Denominator:  Number of sites offering HCV treatment
Targets: Low: <50%
 Medium: >50–<80%
 High: >80%
Potential impact indicators
4.8.14 Decreased morbidity and mortality due to viral hepatitis among IDUs
Data source: HAV/HBV/HCV register data; programme records 
Indicator: a) Number of HCV-related deaths among IDUs 
 b) Number of IDUs experiencing HAV/HBV/HCV-related morbidity
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FRAMEWORK FOR SETTING INDICATORS AND INDICATIVE TARGETS
4.9 Prevention, diagnosis and treatment of tuberculosis (TB)
Availability
4.9.1 Percentage of sites providing services for IDUs and implementing a TB infection control policy
Data source: Programme data 
Numerator: Number of sites providing services for IDUs and implementing  
 a TB infection control policy
Denominator:  Number of sites providing services for IDUs
Targets: Low: <20%
 Medium: >20–<40%
 High: >40%
4.9.2 Percentage of sites providing services for IDUs that have onsite TB diagnosis  
and treatment services
Data source: Programme data 
Numerator: Number of sites providing services for IDUs that have onsite  
 TB diagnosis and treatment services
Denominator:  Number of sites providing services for IDUs
Targets: Low: <20%
 Medium: >20–<40%
 High: >40%
4.9.3 Is TB preventive therapy available for IDUs?
Response: Yes/No
4.9.4 Percentage of sites providing services for IDUs that provide TB preventive therapy
Data source: Programme data 
Numerator: Number of sites providing services for IDUs that provide  
 TB preventive therapy
Denominator:  Number of sites providing services for IDUs
Targets: Low: <20%
 Medium: >20–<40%
 High: >40%
Coverage
4.9.5 Percentage of IDUs with TB status assessed
Data source: Programme data
Numerator: Number of IDUs in whom TB status assessed in the past 12 months
Denominator:  Number of IDUs
Targets: Low: <20%
 Medium: >20–<40%
 High: >40%
4.9.6 Percentage of IDUs started on TB preventive therapy in the past 12 months
Data source: Programme data
Numerator: Number of IDUs started on TB preventive therapy in the past 12 months
Denominator:  Number of IDUs 
Targets: Low: <30%
 Medium: >30–<60%
 High: >60%
36 WHO, UNODC, UNAIDS TECHNICAL GUIDE  WHO DEPARTMENT OF HIV/AIDS  37
4.9.7 Percentage of IDUs completing TB preventive therapy 
Data source: Programme data
Numerator: Number of IDUs completing TB preventive therapy  
 in the past 12 months
Denominator:  Number of IDUs who started TB preventive therapy and were  
 due to complete therapy in the past 12 months
Targets: Low: <30%
 Medium: >30–<60%
 High: >60%
4.9.8 Percentage of IDUs diagnosed with TB and started on treatment in the past 12 months
Data source: Programme data
Numerator: Number of IDUs started on treatment for TB in the past 12 months
Denominator:  Number of IDUs diagnosed with TB in the past 12 months
Targets: Low: <60%
 Medium: >60–<90%
 High: >90%
4.9.9 Percentage of IDUs completing treatment for TB
Data source: Programme data
Numerator: Number of IDUs completing TB treatment in the past 12 months
Denominator:  Number of IDUs who started TB treatment and were due  
 to complete treatment in the past 12 months
Targets: Low: <50%
 Medium: >50–<85%
 High: >85%
Quality
4.9.10 Percentage of sites adhering to WHO guidelines on TB prevention, diagnosis and treatment29 
Data source: Programme monitoring and evaluation 
Numerator: Number of sites offering TB prevention, diagnosis and treatment,  
 and adhering to WHO guidelines29 
Denominator:  Number of sites offering TB prevention, diagnosis and treatment
Targets: Low: <50%
 Medium: >50–<80%
 High: >80%
Comment:  Recent guidance is available on TB/HIV prevention, treatment  
 and care for IDUs.29
Potential impact indicators
4.9.11 Reduced TB-related morbidity and mortality among IDUs
Data source: TB register data; programme records 
Indicator: a) Number of TB-related deaths among IDUs 
 b) Number of IDUs experiencing TB-related morbidity
4.9.12 Ratio of TB among IDUs compared with the general adult population
Data source: TB registration data
Numerator:  Prevalence of TB among IDUs
Denominator: Prevalence of TB among adult general population
Targets: <1 desirable
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